The miR-139-5p regulates proliferation of supratentorial paediatric low-grade gliomas by targeting the PI3K/AKT/mTORC1 signalling Aims: Paediatric low-grade gliomas (pLGGs) are a heterogeneous group of brain tumours associated with a high overall survival: however, they are prone to recur and supratentorial lesions are difficult to resect, being associated with high percentage of disease recurrence. Our aim was to shed light on the biology of pLGGs. Methods: We performed microRNA profiling on 45 fresh-frozen grade I tumour samples of various histological classes, resected from patients aged ≤16 years. We identified 93 microRNAs specifically dysregulated in tumours as compared to nonneoplastic brain tissue. Pathway analysis of the microRNAs signature revealed PI3K/AKT signalling as one of the centrally enriched oncogenic signalling. To date, activation of the PI3K/AKT pathway in pLGGs has been reported, although activation mechanisms have not been fully investigated yet. Results: One of the most markedly down-regulated microRNAs in our supratentorial pLGGs cohort was miR-139-5p, whose targets include the gene encoding the PI3K's (phosphatidylinositol 3-kinase) catalytic unit, PIK3CA. We investigated the role of miR-139-5p in regulating PI3K/AKT signalling by the use of human cell cultures derived from supratentorial pLGGs. MiR-139-5p overexpression inhibited pLGG cell proliferation and decreased the phosphorylation of PI3K target AKT
Introduction
The most commonly diagnosed brain tumours in children are low-grade gliomas (LGGs). Paediatric LGGs (pLGGs) include different entities, as defined by the revised World Health Organization (WHO) classification of central nervous system tumours, which is based on both histological and molecular features [1] . The vast majority of pLGGs are pilocytic astrocytomas (PAs), and they are the ones that have been studied most thoroughly. These tumours are driven by dysregulated signalling through the MAPK/ERK pathway [2] . Less is known about the biological characteristics of less common pLGGs which include, among others, gangliogliomas (GGs), dysembryoplastic neuroepithelial tumours (DNETs) and angiocentric gliomas (AGs).
The location of pLGGs has a major impact on outcome since it determines the tumour's resectability. Infratentorial pLGGs, which occur mainly in the cerebellum, can often be cured by surgery. Supratentorial tumours and those arising in the brainstem are much more difficult to resect, and residual or recurrent disease is, therefore, a common event. The latter are treated with radiotherapy or conventional chemotherapy (e.g. SIOP-LGG 2004 protocol). However, both treatments are associated with substantial long-term toxicity, and these tumours frequently evolve into chronic disease with high morbidity [2] [3] [4] [5] [6] .
The genomic landscape of pLGGs is now being defined. The most frequent genetic alterations are the KIAA1549-BRAF fusion gene and the BRAF V600E single point mutation [3] . Other mutations, such as FGFR1 alterations, are mainly expressed only by specific pLGGs subtypes, such as DNET [7] . Along with the dysregulated MAPK/ERK signalling mentioned above [8] [9] [10] , aberrant activation of the PI3K/ AKT signalling pathway, which can be demonstrated by high levels of phosphorylated AKT (p-AKT), is also a well-documented feature of gliomas, including pLGGs [3, 11, 12] . In some cases, its dysregulation has been linked to genetic changes, such as BRAF fusions, FGFR1 duplications and MYB rearrangements [3] , or epigenetic modifications, but in many cases the mechanism underlying PI3K/AKT pathway activation is still unknown.
MicroRNAs are emerging as major regulators of cancer-related gene expression. In this study, we examined the role of dysregulated microRNA expression in pLGGs, in particular in pLGGs arising in supratentorial areas of the brain, which have the poorest clinical outcomes. Our microRNA profiling analysis of a large series of grade I LGGs from paediatric patients pointed to the PI3K/AKT pathway as one of the most likely 'targets' of dysregulated microRNA expression. In particular, we identified a novel microRNA-mediated mechanism that could be responsible for the hyperactivation of the PI3K/AKT signalling pathway. It involves the markedly down-regulated expression of miR-139-5p, which was observed in the pLGG samples we analysed. Dysregulation of miR-139-5p has been linked to various types of cancer, including adult gliomas and paediatric high-grade gliomas (pHGGs) [13] [14] [15] , but its role in pLGGs has not been investigated yet. Our functional studies in short-term cultures from primary supratentorial pLGGs indicate that the down-regulation of miR-139-5p in these tumours promotes PI3K/AKT pathway activation, thereby enhancing pLGG cell growth.
Tumour samples and controls
microRNA profiling was performed with quantitative PCR (qPCR) (as described below) on RNA extracted from snap-frozen tumour tissue samples from 45 patients (aged 1-16 years) with pLGGs. All underwent surgery at the Bambino Ges u Children's Hospital in Rome or the Gaslini Institute in Genoa between 2014 and 2016. The clinical and pathological features of each case are summarized in Table 1. RNA and DNA used for the analyses were extracted from tumour samples with pathologist-confirmed tumour cell contents of 80% or more. For control purposes, we profiled eight samples (three + a pool of five) of non-neoplastic brain tissue purchased from Ambion-Life Technology (Thermo Scientific, Wilmington, MA, USA) (n = 1: AM7962, Human Brain Total RNA) or Biochain Institute (Newark, CA, USA) (n = 7: R1234035-50, Total RNA-Human Adult Normal Tissue-Brain; R1234035-P, Total RNAHuman Adult Normal Tissue-5 Donor Pool-Brain; R1234035-50, Total RNA-Human Adult Normal Tissue-Brain) and 28 samples (four + a pool of 24) of non-neoplastic brain cerebellum purchased from Biochain Institute (n = 4: R1234039-50, Total RNAHuman Brain cerebellum) or Clontech Laboratories (Takara Bio USA Inc., Shiga, Japan) (n = 1: 636535, Total RNA-Human Brain cerebellum-24 Donor PoolBrain). MicroRNA profiles for the pLGGs were also compared with profiles previously reported by our group for 13 pHGGs, which had been collected between 2005 and 2010 from patients aged from 3 to 17 years [15] . To ensure the comparability of these two cohorts, we reanalysed the microRNA profiles originally reported for the pHGGs [15] using the same normalization procedure and statistical methods employed for comparing the pLGGs with healthy brain tissues, as reported below.
For functional studies, we established short-term cultures of pLGG cells isolated from four primary tumours resected at Bambino Ges u Children's Hospital (Rome) in 2016 (Table 2) . We deliberately selected tumours with non-PA histology, since the biology of these pLGGs has been much less thoroughly explored than that of PAs. We also limited our analysis to supratentorial pLGGs, which are associated with lower miR-139-5p levels, lower resectability rates and worse outcomes than their infratentorial counterparts [11] .
Histology
Formalin-fixed paraffin-embedded (FFPE) samples of each of the 45 pLGGs used in the study were sectioned (3-lm) and stained with haematoxylin and eosin for histology. All tumour diagnoses were then confirmed by consensus decision of three neuropathologists (F.G., M.A. and F.D.C.) using the WHO classification criteria [1] .
Immunohistochemistry
Immunohistochemical studies were performed using anti-PIK3CA (Clinisciences, Nanterre, France), anti-phosphop70 S6 kinase (Thr389) and anti-phospho-Akt (Ser473) (Cell Signalling Technology, Danvers, MA, USA). Paraffinembedded slices of supratentorial pLGG tissues derived from the Pathology Department of the Bambino Ges u Children's Hospital in Rome were used for the staining.
For validation of PIK3CA, phosphorylated-p70 S6 kinase (p-p70 S6K) and phospho-AKT (p-AKT) immunohistochemical assay we tested positive tissues. Hepatocellular carcinoma samples were used for PIK3CA and breast cancer samples were used for p-p70 S6K and p-AKT. For negative control primary antibody was omitted. For the evaluation of PIK3CA, p-p70 S6K and p-AKT staining we used a scoring system. We considered: 0 for no staining; 1+ for barely perceptible staining; 2+ for light to moderate staining; and 3+ for moderate to heavy staining.
RNA extraction of pLGG tissues and cells
Please see Appendix S1 for a detailed description.
Analysis of BRAF status
Each of the 45 pLGGs and the four patient-derived pLGG cell lines were analysed for the two most common genetic alterations found in these tumours -namely, the BRAF V600E point mutation (V600E) and the KIAA1549:BRAF fusion gene [including the three most frequent variants: KIAA1549-BRAF exon 16-exon 9 (K16B9), KIAA1549-BRAF exon 16-exon 11 (K16B11), and KIAA1549-BRAF exon 15-exon 9 (K15B9)].
BRAF fusion analysis BRAF fusion analysis was performed on tumour cDNAs with the Applied Biosystems Viia7 real-time qPCR (RT-qPCR) System, as described by Tian et al. [16] and validated by PCRbased Sanger sequencing through amplification with specific pairs of primers flanking the fusion point between the KIAA1549 (in exon 15 or 16) and BRAF (in exon 9 or 11) genes, as described by Jones et al. [17] . The purified PCR products were sequenced on an ABI 3130 XL DNA analyzer (Applied Biosystems) using the BigDye Terminator v1.1 cycle sequencing kit 
MicroRNA profiling and data analysis
MicroRNA expression profiling was performed on the pLGG tumours using RT-qPCR with Taqman Low Density Array (TLDA) microfluidic cards (Human miR v3.0; Applied Biosystems), which detect the 754 best characterized members of the human microRNA genome. Each reverse transcriptase reaction was performed with specific primers according to Applied Biosystems protocols. The same method had been used to profile the pHGGs in [15] .
Statistical analysis was performed with StatMiner TM software, v. 5.0 (Integromics TM, Granada, Spain). MicroRNA expression levels were normalized by using the global expression normalization method and the comparative threshold cycle method was used to calculate the relative microRNA expression. MicroRNAs with C t values >33 were excluded. Differential expression between groups was assessed with the Limma test, and P values <0.05 were considered to be statistically significant.
A single-assay qPCR for assessment of miR-139-5p expression (Code:002289) was carried out in triplicate using the TaqMan Individual microRNA assays (Applied Biosystems), as previously described [15] . Information regarding microRNA clusters was obtained from miRBase v.21 (http://www.mirbase.org/) [19] . Validated targets of hsa-miR-139-5p were identified by interrogation of the miRTarBase (http://mirtarbase. mbc.nctu.edu.tw/) [20] and literature reports [13, 14] .
MicroRNAs clustering analysis
Dendrograms and heat maps were generated with the use of R (http://www.r-project.org/) using differentially expressed microRNAs as input. The Bray-Curtis method and the average linkage were used in hclust to cluster the samples and heatmap.2 to generate the heat maps [21] .
DIANA mirPath analysis
The microRNAs that were differentially expressed in pLGGs (vs. non-neoplastic brain tissue controls) were loaded into the DIANA mirPath tool (http://snf-515788.vm.okeanos.grnet.gr/) [22] for microRNA pathway analysis. MicroRNAs that were significantly dysregulated in the tumours were then analysed to identify their putative targets.
Patient-derived primary pLGG cell cultures
Culture and characterization Human pLGG samples (described above) were collected immediately after resection and placed in Hank's Balanced Salt Solution supplemented with 0.5% glucose and penicillinstreptomycin. The tissues were triturated with a serological pipette. DNAse I was added (final concentration 0.04%) and left for 20 min. Cell aggregates were then mechanically disrupted with pipettes of decreasing bore size. The single-cell suspension thus obtained was then centrifuged, and the cells suspended in NHA complete medium (Lonza, Basel, Switzerland), counted and plated at a density of 160 000/ml. Prior to use in experiments, isolated primary pLGG cells underwent quality control assays to ensure they were reliable pLGG models. To this end, we verified that the BRAF status of each cell line was identical to that of the parent tumour (as described above in Analysis of BRAF status). For the three primary pLGG cells whose primary tumour did not show any genetic alteration on the BRAF gene, we compared methylation profiles to verify similarity between the primary cell line and the parental tumour.
Immunofluorescence staining (described below) was used to confirm that the cells' histotype-specific glial/neuronal cell biomarker profile was consistent with those described in the literature [23] [24] [25] . The percentage of senescent cells was also evaluated by staining for Senescence-associatedb-galactosidase (SA-b-gal, described below). Cultures with SA-b-gal-positivity rates of 60% or more were excluded from experimentation. During the study, cells were discarded after a maximum of eight passages (about 30 days of culture) or when SA-b-gal-positivity rates reached 60%.
Cell treatments Synthetic miR-139-5p (miRIDIAN microRNA code: C-310568-07; Dharmacon, Cornaredo, Milan, Italy) or negative control (miRIDIAN microRNA negative control code: CN-001000-01; Dharmacon) were transfected into pLGG primary cells at 20 nM using HiPerFect transfection reagent (Qiagen Inc.) for 48 h. miR-139-5p overexpression was confirmed by single assay qRT-PCR. For pharmacological inhibition of PI3K, LY294002 was purchased from Sellekchem, dissolved in DMSO, and stored until used in aliquots at À80°C as 50 mM stock solutions. LY294002 and controls (CTRL) (0.1% DMSO) were diluted in culture medium just before use. After 30 min of treatment with 50 lM LY294002, cells were shifted in normal culture medium for a recovery period of 48 h. Cell growth was evaluated after 48 h by trypan blue exclusion assay. Specifically, the number of cells that did not take up trypan blue (viable cells) was counted both after transfection of synthetic miR-139-5p or negative control. The number of cells that took up trypan blue (nonviable cells) was counted. Each sample was measured in triplicate and repeated at least three times.
DNA methylation array data generation
DNA methylation profiling using the Illumina Infinium HumanMethylation EPIC BeadChip array was performed according to the manufacturer's instructions at the Genetics and Rare Diseases Research Division, Bambino Ges u Children's Hospital, Rome, Italy. In detail 250 ng of DNA was used as input material for freshfrozen tissue and primary cell line samples (after about 15 days of culture). t-Distributed stochastic neighbor embedding (TSNE) analysis was conducted as previously described [26] . Basic array processing and clustering analysis were performed using Illumina GenomeStudio V2011.1 (Methylation Module version 1.9.0, content descriptor version 1.2) (https://www.illu mina.com/techniques/microarrays/array-data-analysisexperimental-design/genomestudio.html) (Illumina, Inc., San Diego, CA, USA). Signal intensities were obtained without background subtraction and normalized to internal controls. Beta-values were used for downstream methylation analyses.
Immunofluorescence studies
SA-b-gal activity
SA-b-gal activity was assessed as described in DebacqChainiaux [28] with minor modifications. Briefly, cells were fixed with 3.6% of formaldehyde in phosphate buffered saline for 4 min at room temperature. Fixed cells were washed and incubated overnight with freshly prepared staining solution at 37°C in the absence of CO 2 . The cells were washed, and coverslips were mounted in antifade medium (Dako Fluorescence mounting medium; Agilent Technologies, Santa Clara, CA, USA). Images were acquired using a Leica DM2500 microscope (Leica Microsystems, Wetzlar, Germany) with a 209/0.40 NA objective. Pictures were taken using the ISCapture software and processed with Adobe Photoshop (Mountain View, CA, USA) to adjust brightness and contrast. The percentage of positive cells was evaluated by dividing the number of blue cells on the total number of cells in the field [8] .
Western blotting
Statistical analysis
Data reported in this paper are the means AE SD of at least three independent experiments each performed in triplicate. Unpaired t-test and paired t-test were performed wherever appropriate using GraphPad Prism software version 6.0 (La Jolla, CA, USA), P values <0.05 were considered to be statistically significant.
Results

Characteristics of the pLGG cohort
The clinical and pathological features of the 45 primary pLGGs we analysed are summarized in Table 1 . Thirty (67%) of the tumours were PAs, eight (18%) were gangliogliomas (GGs), four (9%) were DNETs, two (4%) were AGs and one (2%) was a glioneuronal tumour. Patients' age at diagnosis ranged from 1 to 16 years (median 7 years; mean 7.1 years). Three were located in the brain stem (two PAs, one GG). The other 42 included comparable numbers of infratentorial (n = 25) and supratentorial (n = 17) tumours. KIAA1549:BRAF fusion genes were common, in accordance to literature [3] . The K16B9 variant -the one most frequently encountered -was present in 18 (27%) pLGGs, most of which (13, 52%) were infratentorial. BRAF fusions were less common in the supratentorial tumours [5/18 (29%) ]. Three pLGGs harboured the BRAF V600E point mutation (two infratentorial and one supratentorial).
MicroRNA profiles of pLGGs
We measured the expression levels of 754 microRNAs in the 45 pLGGs described above and compared them with non-neoplastic brain (CTRL). The results were also compared with profiles previously reported by our group for 13 pHGGs (glioblastoma multiforme, n = 8; anaplastic astrocytoma, n = 5) [15] . The TLDA analysis reported similar high detection rates in all the three tissue groups [474 (63%) of the 754 microRNAs were identified in pLGGs, 436 (58%) in pHGGs and 368 (49%) in CTRL].
The differentially expressed microRNAs (Tables S1 and  S2 ) were plotted using hierarchical clustering, as reported in Figure 1 . Some of the most striking alterations involved upregulation of microRNAs with documented oncogenic effects in many tumours (e.g. miR-21 and members of the miR-17-92 cluster) [15, 30] or down-regulation of microRNAs with reported oncosuppressive effects in various settings. The latter included miR-218 [31] , miR-124 [30] , miR-487b [32] and miR-139-5p [33] [34] [35] [36] [37] .
We further evaluated the microRNAs profiles of supratentorial and infratentorial tumours with respect to non-neoplastic brain or normal cerebellum as CTRL, respectively. Among supratentorial tumours, 69 microRNAs displayed significant tumour-related upregulation (n = 28) or down-regulation (n = 41) (P < 0.05) ( Tables 3 and 4) . Whereas in the analysis between infratentorial tumours and normal cerebellum 109 microRNAs displayed significant tumour-related up (n = 52) or down-regulation (n = 57) (P < 0.05) (Tables S3 and S4) .
Among dysregulated microRNAs, miR-139-5p was noteworthy since it was significantly down-regulated only in supratentorial pLGGs (Table 4 ) and its downregulated expression has been documented in highgrade gliomas (adult and paediatric) [13] [14] [15] , but still unexplored in pLGGs.
Interestingly, the number of differentially expressed microRNAs in pLGGs and pHGGs was lower than that observed when pLGGs were compared with non-neoplastic brain tissues (Tables S5 and S6 ). The pLGG and pHGG samples segregated into two main clusters (Figure S1 ). The first (left side of Figure S1 ) comprised 19 of the 45 pLGGs. The second (right side of Figure S1 ) was more heterogeneous and contained two subclusters: one contained 21 pLGGs, the second included both pLGGs and pHGGs. This finding highlighted the existence of a gradient of microRNA expression reflecting internal variation within the pLGGs cohort. Notably, the expression levels of miR-139-5p in pLGGs resembled those found in pHGGs.
PI3K/AKT signalling is controlled by microRNAs that are dysregulated in pLGGs
To explore the functional implications of the microRNA profile of our pLGGs cohort, we used the DIANA miRPath tool to identify signalling pathways likely to be vulnerable to the altered microRNA expression levels found in these tumours. As summarized in Table 5 , after the broader category pathways in cancer, the PI3K/AKT pathway contained the highest number of components putatively targeted by the microRNAs dysregulated in our pLGG cohort. This finding is consistent with recent reports of aberrant PI3K/AKT/mTOR signalling in paediatric gliomas, both high-and low-grade [11, 12] . This hyperactivation has been attributed to genetic and epigenetic alterations in certain glioma subsets, but in many cases the cause is still unknown. We noted with interest, therefore, that PIK3CA, which encodes the catalytic subunit of phosphatidylinositol 3-kinase (PI3K), is a validated target of miR-139-5p, as demonstrated by luciferase assay in Krishnan et al. [38] . The marked dysregulation of this tumour-suppressor microRNA in pLGGs was documented for the first time in our cohort (Tables S2 and 4) .
Down-regulation of miR-139-5p in pLGGs favours tumour-cell proliferation
Taken together, these findings suggested that downregulation of miR-139-5p in supratentorial tumours might contribute to the development of pLGGs by derepressing expression of PIK3CA, thereby favouring aberrant activation of the PI3K/AKT pathway. To address this hypothesis, we firstly investigated the expression of PIK3CA by performing immunohistochemistry assay in pLGG tissues derived from AG, DNET and GG tumours, which are predominantly supratentorial. As reported in Figure S2 , pLGGs showed positive staining for PIK3CA, with an average of 25% positive cells and a 2+/3+ score. Then, we carried out in vitro experiments in primary monolayer cultures of pLGG cells isolated from patient-derived samples of AG, DNET and GG. The characteristics of these cells are summarized in Table 2 and their growth curves and description are reported in greater detail in Figures 2, 3 , S3 and S4. The immunofluorescence staining confirmed the glial and/ or mixed neuro-glial nature of the primary pLGG cells. For all the histological types, cells were positive for the glial markers vimentin and S100, while the level of glial fibrillary acidic protein positivity was more variable ranging from 20% to 70%. In DNET and GG samples, we also detected frequent positivity for NeuN and Synaptophysin, neuronal markers, which conversely were absent in the AG. Therefore, the immunofluorescence staining together with the methylation profiling, a method to evaluate the similarity among tumours samples and their derived primary cells [10, 26, [39] [40] [41] , indicate that our primary cells are a suitable and trustworthy model to study supratentorial pLGGs biology. MiR-139-5p levels in supratentorial pLGGs were markedly lower than those in non-neoplastic total brain tissues (Table 4, Figure 4a ). Down-regulation of miR-139-5p was also evident in our patient-derived primary pLGG cell cultures at levels comparable to those of the primary tumours they derive from (Figure 4b) . Overexpression of miR-139-5p in these cells ( Figure S5 ) resulted in significantly reduced proliferation, which was evident in all three histological types represented (Figure 4c-f) , while not affecting cell death (data not shown).
miR-139-5p controls PI3K/AKT/mTORC1 signalling in supratentorial pLGGs
The results of the previous experiments provide evidence that down-regulation of miR-139-5p plays a role in supratentorial pLGG cell growth. To determine whether its effects on cell growth were mediated by derepressed PI3K activity, we assessed the effects of miR-139-5p overexpression on the phosphorylation of the PI3K target, AKT. At baseline, p-AKT levels were high in all the cell cultures tested, but they dropped markedly after miR-139-5p overexpression (Figure 5a-c) . In order to investigate whether miR-139-5p effect was directly mediated by PI3K inhibition, we examined proliferation and p-AKT levels in primary pLGG cells before and after treatment with the direct PI3K inhibitor LY294002. Our results showed that LY294002 treatment caused a significant impairment of cell proliferation (Figure 5d-g ) and decreased levels of p-AKT (Figure 5h-j) . Again, we did not observe any significant effect on cell death (data not shown).
One of the downstream effectors of PI3K/AKT signalling is mammalian target of rapamycin complex 1 (mTORC1). Activation of this complex has already been reported in pLGGs [11] , and hyperactivation of the PI3K/AKT/mTORC1 axis has been implicated in the increased cell proliferation of these tumours [12] . We therefore wondered if mTORC1 inhibition was involved in the antiproliferative effects produced in pLGG cells Single-cell monolayers (on the average present after 7 days of culture) were subjected to immunofluorescence staining for glial markers (S100, vimentin, glial fibrillary acidic protein] and neuronal markers (NeuN, synaptophysin). In detail, (a) AG-derived cells (pLGG1) show positivity for glial markers only [23] , whereas (b) DNET-derived cells (findings shown for pLGG2 are also representative of DNET line pLGG3) [24] and (c) GG-derived cells (pLGG4) expressed both glial and neuronal markers [25] . The positivity and negativity of the staining of the observed glial and neuronal markers was concordant with immunohistochemical staining results obtained by pathologists on formalin-fixed paraffin-embedded samples of the tumours from which pLGG lines 1, 2 and 4 were derived (data not shown). Scale bars, 50 and 100 lm (high magnification insert). AG, angiocentric glioma; PLGG, paediatric low-grade gliomas; GG, gangliogliom; DNET, dysembryoplastic neuroepithelial tumour. by miR-139-5p overexpression. As shown in Figure 6a -c, cells transfected with miR-139-5p displayed significantly decreased p-p70 S6K, a hallmark of mTORC1 activation. A comparable reduction was produced when PI3K was inhibited with LY294002 (Figure 6d-f) . Furthermore, immunohistochemical staining for p-p70 S6K and p-AKT were performed in pLGG samples. As reported in Figures S6 and S7 , tumours showed p-p70 S6K and p-AKT positive staining with an average of more than 10% positive cells and a score 2+ for both assay. Taken together, these data indicate that the down-regulated expression of miR-139-5p in primary supratentorial pLGG cells increases their proliferation by derepressing PI3K/AKT signalling and that its effect is mediated by mTORC1, as summarized in Figure 7 .
Discussion
MicroRNAs have been identified as pivotal players in a variety of cancers [42, 43] . Thus far, however, the research conducted on these noncoding RNA species in Figure 3 . Methylation analysis of primary patient-derived pLGG cells confirms their identity. DNA methylation profiling was performed on the three tumours (an AG and two DNETs) that did not show any genetic BRAF alterations and their primary pLGG derived cells. TSNE (t-distributed stochastic neighbor embedding) analysis of the whole genome DNA methylation data show a close similarity between patient-derived pLGG cell lines, their primary tissues and the group of pLGGs they derive from (AG and DNET) but they diverge from other paediatric low-grade tumours and non-neoplastic cortex. pLGG1, AG tissue and patient-derived cells; pLGG2 and pLGG3, DNET tissues and their respective patient-derived cells (see Table 2 ). Colour legend of the TSNE plot as follows: PXA (brown); GG (orange); Cortex (light blue); AG (black); PA GG hemispheric (light purple); PA Infratentorial (purple); DNET (blue); PA midline (yellow). PLGG, paediatric low-grade gliomas; AG, angiocentric glioma; DNET, dysembryoplastic neuroepithelial tumour; GG, ganglioglioma; PA, pilocytic astrocytoma; PXA, pleomorphic xanthoastrocytoma.
pLGGs has been largely descriptive. Moreover, the conclusions that can be drawn from these studies are frequently limited by the small number of cases analysed [31, 44] , the inclusion of high-grade gliomas besides pLGGs [45, 46] or the inclusion of adult patients [32] . Our study differs from its predecessors in several respects. Our microRNA profiling study was conducted on fresh-frozen samples of 45 pLGGs, all of which were grade I tumours resected from patients 16 years of age or younger. We identified 93 microRNAs whose differential expression distinguished the pLGGs from controls. Since a number of microRNAs display directional and quantitative similar dysregulation in pHGG, these microRNAs are more likely to play a role in paediatric gliomas in general than in specific WHO classes of pLGGs. In fact, the down-regulated expression of miR487b, miR-323a-3p and miR-410 -all members of the 379-656 cluster -has already been described in gliomas of various grades [32, 47, 48] . Likewise, upregulated expression of miR-18a-5p and miR-20a-5p (both belonging to the miR 17-92 cluster) and of miR-21-5p has been found in pLGGs [32] and pHGGs [15, 49, 50] , as well as in other types of brain tumours [51] [52] [53] . Thanks to the results of this first part of the study we were able to identify specific microRNA profiles for pLGGs that will be object of future experimental investigations.
The importance of the PI3K/AKT/mTOR pathway that emerged from our microRNA pathway analysis was not surprising. Along with the MAPK/ERK axis, it is one of the pathways most frequently upregulated in cancers, including pLGGs [2, 3, 54, 55] . Aberrant activation of PI3K/AKT/mTOR signalling in pLGGs has been reported in association with several genetic alterations, including BRAF fusions, FGFR1 duplications, and MYB rearrangements [3] , which are present at different frequencies in the various pLGGs histologies, with the last two genetic alterations that have been more specifically detected in DNET and AG, respectively. Epigenetic mechanisms have been investigated as alternative activators of PI3K signalling in these tumours. For instance, promoter methylation and consequent silencing of expression of the gene encoding phosphatase and tensin homolog (PTEN) -a major negative regulator of PI3K signalling -has also been documented in some gliomas, and its frequency correlated positively with tumour grading [11, 56] . Therefore, PTEN promoter methylation, too, is unlikely to account for the oncogenic activation of the PI3K/AKT signalling in most grade I pLGGs. These considerations heightened our interest in the marked down-regulation of miR-139-5p, which was found in all examined grade I pLGGs. This microRNA has been demonstrated to be a validated negative regulator of the PIK3CA gene, which encodes the catalytic subunit of the PI3K [38] . The oncosuppressive effects of miR-139-5p have been described in a variety of solid tumours [37, 38, [57] [58] [59] , including adult high-grade gliomas [13, 14] . Nonetheless, neither the level of expression of miR-139-5p or its biological role has never been explicitly investigated in pLGGs.
Our functional characterization of miR-139-5p loss in grade I pLGGs provides the first evidence that this alteration may be a key driver of oncogenic activation of the PI3K/AKT/mTORC1 pathway in these tumours. As illustrated in Figure 7 the down-regulated miR-139-5p expression in supratentorial pLGGs significantly enhances activation of PI3K/AKT/mTORC1 signalling, as reflected by the high phosphorylation levels of AKT and p70 S6K, which dropped markedly after miR-139-5p overexpression, and the biological outcome is a substantial increase in tumour-cell proliferation. MiR-139-5p down-regulation could conceivably act alone to activate this pathway. However, there is no reason to exclude the possibility of additive effects in the presence of the genetic and/or epigenetic mechanisms of activation discussed above. It is also important to recall that miR-139-5p down-regulation might produce additional tumour-promoting effects by depressing other targets, which include numerous genes with documented oncogenic effects in gliomas and in other cancers as well (e.g. FOS, HRAS, JUN, MCL1, NOTCH1, ELTD1, ZEB1 and ZEB2) [13, 14, 38, 57, [59] [60] [61] . These conclusions are based on the results of studies on the restored expression of miR-139-5p in primary cultures of patient-derived supratentorial pLGG cells, whereas the few functional studies conducted in this area have utilized immortalized pLGG cells, such as the PA-derived Res186 line and/or Res259 cells, originally derived from a grade II diffuse astrocytoma [12, [62] [63] [64] . A major drawback of these cell lines is that they harbour genetic alterations that are relatively rare in pLGGs, and it is unclear to what extent they represent the primary lesions [12, 65, 66] . Previous attempts to use short-term primary cultures of patient-derived pLGGs have been hampered by markedly reduced growth secondary to oncogene induced senescence [8] [9] [10] . Protocol differences might contribute to explain why our efforts were more successful. It is worth noting, however, that the unsuccessful attempts cited above all involved the use of cells isolated from PAs, whereas the cells we used came from non-PA pLGGs. This choice was based on our purpose to elucidate the biology of pLGGs arising in supratentorial structures of the brain, where PAs are less common. Interestingly, however, we also encountered slow growth and senescence in our non-PA cultures ( Figure S3a-c) . Senescence rates varied widely (even between cultures of cells representing the same pLGG histotype, data not shown), and they generally -but not alwaysincreased over time. For instance, in some cultures, high rates were already observed after the first few passages. By carefully selecting the cultures destined for experiments particularly by analysing their whole genome methylation profile (Figure S4 ), demonstrated to be a reliable method to pinpoint the identity of a broad range of brain tumours [10, 26, [39] [40] [41] , but also continuously monitoring their senescence rates over time, we were able to complete short-term experiments and our assessment of these cells indicates that they are likely to provide reliable representations of the pLGGs seen in the clinic. Therefore, our primary patient-derived pLGG cells present many benefits in comparison with the few immortalized cell lines that have been used until now and represent a more reliable model to study the biology of these tumours, that otherwise would be hardly addressed. The major disadvantage of these cultures is Figure 6 . Phosphorylation of phosphorylated-p70 S6 kinase (p-p70 S6K) in pLGG cells subjected to miR-139-5p overexpression or LY294002 treatment. The overexpression of miR-139-5p (a-c) and direct PI3K inhibition for 30 min with 50 lM LY294002 followed by a 48 h recovery period in normal medium (d-f) both strongly reduced p70 S6K phosphorylated levels (p-p70 S6K) while leaving unaffected the level of total p70 S6K.
that they represent short-term cultures with a low proliferation rate and the number of experiments that can be performed is limited. Consequently, these primary models can be used only to answer to specific and well-defined biological questions. Interestingly, the methylation profiling allowed us to note that shortterm primary cells could be more or less closer to their primary tumour, probably reflecting the heterogeneity of the cellular composition of the primary pLGG tumours analysed. Since morbidity and mortality, particularly due to disease progression, represent a significant problem in children affected by pLGGs even after many years from diagnosis [5, 6, 67] there is an urgent need for the identification and use of less toxic therapies, such as molecular targeted agents, in children with LGGs [67] . In this context, our primary patients'-derived cellular models represent a proper and trustable in-vitro model to test molecular targeted compounds.
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